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ABSTRACT

There are few more devastating complications of musculoskeletal trauma than
compartment syndrome (CS). It occurs secondary to elevated pressure within a
closed osseofascial compartment, leading to microvascular dysfunction, hypoperfusion of the tissues, cellular anoxia and ultimately cell death. The aim of this
thesis was to prove that CS leads to a systemic inflammatory response, and to
examine the specific cytokines/chemokines associated with CS. Twenty-four
cytokines/chemokines were measured in a rat model of CS. Additionally,
microvascular dysfunction, tissue injury and inflammatory response following the
neutralization of pro-inflammatory cytokine, TNF-α, at the time of fasciotomy
were assessed using intravital video microscopy (IVVM). The results of our
studies were the first to confirm that CS is associated with an acute inflammatory
response, and that neutralization of TNF-α at the time of fasciotomy provides
some protection against tissue injury due to CS.
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CHAPTER 1: INTRODUCTION

1.1 COMPARTMENT SYNDROME
Compartment syndrome (CS) results from increased pressure within a
closed osseofascial compartment; microvascular compromise, cellular anoxia
and ultimately cell death ensues (Whitesides, Haney et al. 1975, Mubarak, Owen
et al. 1978, Rorabeck and Clarke 1978, Matsen, Winquist et al. 1980, Hartsock,
O'Farrell et al. 1998). CS is a surgical emergency, whereby fasciotomy is the only
effective treatment (Tzioupis, Cox et al. 2009).
The etiology of CS is varied and commonly includes fractures, burns,
crush injuries, ischemia-reperfusion injury, exertion, and prolonged limb
compression. Less frequent causes of CS include bleeding disorders (Hope and
McQueen 2004), lithotomy position (Mathews, Perry et al. 2001), hypothyroidism
(Hsu, Thadhani et al. 1995), and snake bites (Vigasio, Battiston et al. 1991).

1.2 DIAGNOSIS
The diagnosis of CS is currently rooted in clinical signs and symptoms.
Prompt diagnosis is critical in order to minimize long-term complications. A high
suspicion must be maintained at all times; knowledge of the early clinical signs
and symptoms, as well as a recognition of high-risk patients are vital to its timely
diagnosis (Matsen, Winquist et al. 1980, McQueen, Gaston et al. 2000). Risk
factors include male gender, young age, tibial fracture, high-energy forearm
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fracture, femoral diaphyseal fractures, bleeding diathesis, and anticoagulation
(McQueen, Gaston et al. 2000).
Two of the hallmark clinical signs of early CS include pain out of
proportion to the injury and pain on passive stretch (PPS) of the affected
compartment (Whitesides and Heckman 1996). In children, or in patients whose
level

of

consciousness

is

altered,

progressively

increasing

analgesia

requirements may be an early sign of developing CS (Bae, Kadiyala et al. 2001).
Pain out of proportion to the injury and PPS are often the only findings that
precede neurologic dysfunction of the affected compartment. Unfortunately the
sensitivity of these clinical signs in combination is alarmingly low (13 - 19%),
while the specificity is high (97%) (Whitesides and Heckman 1996, Ulmer 2002).
The absence of pain and PPS is, perhaps, more useful in ruling out CS (Ulmer
2002) than diagnosing it when they are present.
A

palpably

tense

compartment,

resulting

from

increased

intra-

compartmental pressure (ICP), is recognized as an early physical sign of CS
(Mubarak, Owen et al. 1978). Any patient being evaluated, or who is at high risk
for CS, should have their dressings or cast removed for thorough assessment.
Serial examination is also paramount, as the onset of CS is unpredictable.
It is important to note that the absence of a distal pulse and/or pallor of the
affected limb are not features of CS. Likewise, paresis and/or paralysis of the
muscles of the involved compartment are late signs of CS (Matsen and Clawson
1975, Ulmer 2002). These are important distinctions to draw, as waiting for all
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clinical signs and symptoms to be present for diagnosis would lead to poor
functional outcomes, and increased morbidity and mortality.
As an adjunct to the physical examination, intra-compartmental pressure
monitoring is available. In patients who are unable to communicate verbally, for
example pediatric or obtunded patients, invasive compartment pressure
monitoring can provide valuable objective information in diagnosing acute CS
(Gelberman, Garfin et al. 1981, Hargens, Akeson et al. 1989). While there are
multiple methods of measuring compartment pressures, the use of electronic
transducer-tipped systems are the most accurate and are not dependent on limb
position or height of the transducer (McDermott, Marble et al. 1984, Willy,
Gerngross et al. 1999).
While ICP monitoring can serve as a valuable adjunct in the diagnosis of
acute CS, there remains no consensus regarding the threshold at which
fasciotomy is necessary. Multiple absolute pressure thresholds have been
suggested, and include 30 mmHg (Mubarak, Owen et al. 1978), 40 mmHg
(Schwartz, Brumback et al. 1989), and 45 mmHg (Matsen, Winquist et al. 1980).
A differential pressure threshold has been popularized, which theorizes that
tissue ischemia begins when the difference between the ICP and the diastolic
blood pressure is 20 mmHg (Whitesides, Haney et al. 1975). This differential
pressure threshold has since been expanded to 30 mmHg based on
retrospective observation that this value led to no missed cases of CS (McQueen
and Court-Brown 1996). The differential pressure threshold is useful clinically in
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hypotensive trauma patients, and has a lower overall rate of fasciotomy when
compared to the absolute pressure threshold (McQueen and Court-Brown 1996).
The diagnosis of CS requires a thorough evaluation of patients,
maintenance of a high suspicion, awareness of risk factors, and if any doubt
exists, frequent serial examinations with the use of invasive ICP monitoring. To
date there is no reliable objective diagnostic test for CS; therefore clinical
judgment remains at the forefront of diagnosis in order to prevent the
catastrophic complications of a late diagnosis or a misdiagnosis.

1.3 TREATMENT
CS is a surgical emergency, as it is both a limb- and life-threatening
condition. Treatment involves emergent surgical decompression of the affected
limb by fasciotomy, regardless of the underlying cause of CS. CS, however,
occurs most frequently following fracture of the tibia; approximately 6% of
patients under the age of 35 with a tibial diaphyseal fracture develop
compartment syndrome (McQueen, Gaston et al. 2000).
There are multiple described techniques for fasciotomy of the lower leg,
with the two-incision technique being the preferred method (Appendix C). In brief,
it involves incising and releasing the fascial layer that surrounds the affected
compartment. This facilitates tissue swelling, allowing the compartments to
expand and therefore decreasing the ICP. All non-viable tissue is debrided,
wounds are left open, and a repeat debridement is performed 48-72 hours later.
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At the second operation, wounds are either closed primarily, with skin grafting, or
occasionally with more advanced reconstructive techniques.

1.3.1 Anatomy of the Lower Leg
The lower leg has four distinct osseofascial compartments: anterior,
lateral, deep posterior, and superficial posterior (Figure 1.1). The anterior
compartment includes the extensor muscles of the foot and ankle. The lateral
compartment contains the peroneal muscles, which evert the foot. The posterior
compartments, both deep and superficial, include the flexor muscles of the foot
and ankle.

1.4 COMPLICATIONS OF COMPARTMENT SYNDROME
CS is both a limb and life-threatening condition, and despite appropriate
and timely treatment, devastating complications can ensue. In a systematic
review of 1920 cases of CS, overall 5.5% of patients required an amputation, and
there was a 3.3% CS-associated mortality rate (Hayakawa, Aldington et al.
2009). Timing of fasciotomy is critical: when comparing fasciotomy within 6 hours
to delayed fasciotomy beyond 12 hours, there was a higher rate of amputation
(14% vs. 3.2%) and death (4.3% vs. 2.0%) (Hayakawa, Aldington et al. 2009). A
retrospective review of 336 combat casualties in Iraq and Afghanistan over a 20month period found that delayed fasciotomy resulted in double the rate of
amputations, and increased the mortality rate threefold, as compared with
patients who had early fasciotomy (Ritenour, Dorlac et al. 2008).

	
  

Figure 1.1.

7	
  

Cross-section of the lower leg. The lower leg contains two bones

(tibia and fibula) and is divided into four distinct osseofascial
Figure 1.1: Cross-section of the lower leg. The lower leg consists of two
compartments: (1) anterior compartment (containing tibialis
bones (tibia and fibula) and 10 major muscles (tibialis anterior, extensor
anterior, extensor hallucis longus, extensor digitorum longus,
digitorum longus, extensor hallucis longus, peroneus longus, peroneus brevis,
peroneus tertius, the deep peroneal nerve and the anterior tibial
soleus, gascrocnemius, tibialis posterior, flexor digitorum longus, flexor hallucis
vessels); (2) lateral compartment (containing peroneus longus,
longus). The muscles are separated by fascia into four compartments (anterior,
peroneus brevis, superficial peroneal nerve); (3) deep posterior
lateral, superficial posterior and deep posterior).
compartment (contains tibialis posterior, flexor digitorum longus,
Reproduced with permission from Lawendy and Sanders (2010).
and flexor hallucis longus, tibial nerve and posterior tibial vessels);
(4) superficial posterior compartment (contains gastrocnemius,
!

soleus, and plantaris, and the sural nerve).
8!
Reproduced with permission from Lawendy and Sanders (2010).
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Infection is a common complication following fasciotomy, with high rates of

7.3% even when treated early, versus 28% if fasciotomy is delayed greater than
12 hours (Williams, Luchette et al. 1997). A retrospective study of 60 patients
found that 70% of patients had long-term neurologic dysfunction following
fasciotomy (62% weakness, 66% paresthesia, 71% dysaesthesia) (Dover,
Memon et al. 2012). Fitzgerald et al performed a retrospective review of patient
outcomes over an 8-year period, and reported that 77% of their patient
population had residual sensory deficits around their wounds, and 10% had
chronic pain (Fitzgerald, Gaston et al. 2000). In another study 15.4% of all
patients have residual pain at rest, and 26.9% have pain with exertion following
CS (Frink, Klaus et al. 2007).

1.5 PATHOPHYSIOLOGY
The pathophysiological mechanism of the tissue injury seen in
compartment syndrome remains only partially understood. The literature
supports raised ICP as the initial insult, which then leads to microvascular
dysfunction. Damage to the microcirculatory system results in hypo-perfusion,
causing cellular anoxia and muscle death (Sheridan and Matsen 1975,
Whitesides, Haney et al. 1975, Rorabeck and Clarke 1978, Matsen, Winquist et
al. 1980, Harvey, Sanders et al. 2012). In contrast with complete ischemia, CS
causes tissue necrosis despite a patent macrocirculatory system: patients with
CS almost always have a palpable distal pulse (Seddon 1966, Lawendy, Bihari et
al. 2015).
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Live in vivo imaging using intravital video microscopy (IVVM) of the

microcirculatory system in an animal model of CS, has demonstrated that raised
ICP causes significant impairment in capillary perfusion. Under normal
physiological conditions there is continuous flow through the capillary beds.
Raised ICP, however, causes a shift in perfusion toward non-perfused capillaries
(NPC), and intermittently perfused capillaries (IPC) (Lawendy, Sanders et al.
2011, Lawendy, Bihari et al. 2015). Decreased tissue perfusion leads to
inefficient nutrient and gas exchange for the metabolic demands of the tissue.
NPCs have no ability for nutrient or gas exchange, and represent a state of
ischemia. The presence of some continuously perfused (CPC), IPC, and NPC in
the same muscle bed therefore suggests that CS is a low-flow ischemic state.
IVVM has also been able to demonstrate that the microvascular
dysfunction seen secondary to raised ICP is associated with rapid activation of
leukocytes in post-capillary venules, suggesting the inflammatory pathway may
play a role in the tissue injury seen in CS (Lawendy, Sanders et al. 2011,
Lawendy, Bihari et al. 2015). We know from complete ischemia and reperfusion
(I/R) literature that the re-introduction of oxygenated blood into an ischemic
muscle bed causes a significant activation of leukocytes (Gute, Ishida et al. 1998,
Lakshminarayanan, Lewallen et al. 2001). It has been well documented in
complete I/R that increasing ischemia time causes increasing accumulation of
activated leukocytes in the post-capillary venules. Leukocyte activation leads to
increased vascular permeability to plasma protein leakage, tissue edema, and
increased interstitial pressure. This increased interstitial pressure is believed to
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physically compress capillaries, leading to failure of capillaries to reperfuse upon
restitution of blood flow to ischemic tissue. The microvascular dysfunction
associated with reperfusion injury is known as no-reflow phenomenon, whereby
despite successful resolution of ischemia there is impaired nutrient and gas
exchange to meet the metabolic demands of the tissue (Sexton, Korthuis et al.
1990, Kurose, Anderson et al. 1994, Gute, Ishida et al. 1998). A strong
correlation has been noted between the number of leukocytes in the capillaries of
post ischemic tissue and the percentage of capillaries exhibiting no-reflow
(Engler, Dahigren et al. 1986, Barroso-Aranda, Schmid-Schonbein et al. 1988,
Del Zoppo, Schmid-Schonbein et al. 1991, Gute, Ishida et al. 1998).
Further support that activated leukocytes are involved in no-reflow
phenomenon is observed in leukopenic models of complete I/R. The
microvascular dysfunction of no-reflow in re-perfused myocardium, brain, and
skeletal muscle tissue has been abolished in neutrophil-deplete models of
complete I/R (Schmid-Schonbein, Shih et al. 1975, Barroso-Aranda, SchmidSchonbein et al. 1988, Jerome, Smith et al. 1993). Leukopenia does not,
however, appear to be protective in restoring or maintaining perfusion following a
CS insult (Lawendy, Bihari et al. 2015). Additionally, a greater impairment to the
metabolic state and structural integrity of skeletal muscles has been shown in
canines subjected to 3 hours of hind limb raised ICP, followed by 2 hours of
reperfusion, compared to animals undergoing 3 hours of complete ischemia,
followed by 2 hours of reperfusion (Heppenstall, Scott et al. 1986). These
findings suggest that while compartment syndrome falls within the spectrum of
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ischemia – reperfusion injury, the pathophysiology of tissue injury is distinct from
that of complete I/R.

1.6 LEUKOCYTE ACTIVATION
Live in vivo studies have demonstrated that the microvascular dysfunction
associated with CS occurs in conjunction with leukocyte accumulation and
activation in the post capillary venules (Lawendy, Bihari et al. 2015). Leukocyte
activation occurs via a series of events, which ultimately results in extravasation
of the leukocyte from the blood stream to the extravascular tissue. With the
reintroduction of oxygenated blood after an ischemic insult, reactive oxygen
species (ROS) are generated, which promote a pro-inflammatory stimulus.
Additionally, ROS modify the expression of adhesion molecules on the surface of
leukocytes and endothelial cells, resulting in their activation (Gute, Ishida et al.
1998). In the initial phase of leukocyte activation, leukocytes come into contact
with the endothelial cell surface and begin to roll along the endothelium of the
post-capillary venule following tissue injury or inflammation (Atherton and Born
1973, Carlos and Harlan 1994). Leukocytes are considered rolling if they remain
in contact with the vessel wall but do not remain static. A family of three proteins,
known as selectins, mediates rolling; they include E- (endothelial), P- (platelet),
and L- (leukocyte) selectin, where E- and P-selectin are expressed by stimulated
endothelial cells, and L-selectin is expressed by leukocytes (Bevilacqua and
Nelson 1993, Carlos and Harlan 1994).
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In the second phase of leukocyte activation, leukocytes become firmly

adherent to the endothelium. A leukocyte is considered adherent if it remains
fixed to the vessel wall. Adhesion is modulated via leukocyte integrins; the
transmembrane glycoprotein family CD11/CD18 has been identified as the most
likely integrins to modulate neutrophilic adhesion (Dana, Fathallah et al. 1991,
Gute, Ishida et al. 1998). Binding of chemokines, cytokines, or chemoattractants
can increases the affinity of the integrins for endothelial adhesion proteins
(Carlos and Harlan 1994). The counter-receptor for CD11/CD18 expressed by
endothelial cells is the intercellular adhesion molecule-1 (ICAM-1) (Horgan, Ge et
al. 1991, Ma, Lefer et al. 1992).
Once firmly adherent to the endothelium, activated leukocytes extravasate
into the subendothelial matrix towards sites of inflammation or injury, where they
are thought to be responsible for parenchymal injury via release of oxidants and
hydrolytic

enzymes.

Additionally,

extravasated

leukocytes

disrupt

the

microvascular barrier, increasing the permeability of intravascular proteins into
the extravascular space and causing tissue edema (Gute, Ishida et al. 1998).

1.7 SYSTEMIC CYTOKINES/CHEMOKINES
Cytokines comprise a group of cell-derived secreted proteins that effect
the interactions and communications between cells (Feghali and Wright 1997,
Zhang and An 2007). Cytokine is a general term, and includes cytokines
produced

by

lymphocytes

(lymphokines),

and

monocytes

(monokines).

Chemokines are a subset of cytokines with chemotactic properties. Interleukins
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are cytokines that are produced by leukocytes, and exert their effects on other
leukocytes. Cytokines can exert their effects on the cell which secretes them
(autocrine action), on nearby cells (paracrine action), or at distant sites
(endocrine action) (Zhang and An 2007).
Cytokines are responsible for the make-up of the cellular infiltrate, cellular
activation, and the initiation of the systemic response to inflammation. Most
cytokines are multifunctional and have redundant activities. They may act
synergistically or antagonistically, and can exhibit both negative and positive
regulatory effects on their target cells. Cytokines bind with high affinity to cell
surface receptors on their target cells, initiating a series of intracellular signal
transduction pathways (Feghali and Wright 1997).
Pro-inflammatory cytokines are predominantly produced by activated
macrophages, and result in the upregulation of inflammatory reactions (Zhang
and An 2007). A number of cytokines have been implicated in mediating acute
inflammatory reactions. Interleukin 1 (IL-1), and tumor necrosis factor alpha
(TNF-α) are two of the primary cytokines that mediate acute inflammation, and
have pro-inflammatory properties (Feghali and Wright 1997).

1.8 TUMOR NECROSIS FACTOR ALPHA
TNF-α is a potent pro-inflammatory cytokine released by macrophages
(innate immune cells) following trauma, inflammation, or infectious stimulation
(Stein and Gordon 1991). TNF-α plays a role in the regulation of cell proliferation,
survival, differentiation, and apoptosis (Parameswaran and Patial 2010). TNF-α

	
  

14	
  

has been found in multiple I/R studies to be acutely upregulated following the
initiation of reperfusion (Caty, Guice et al. 1990, Brock, Lawlor et al. 1999,
Krishnadasan, Naidu et al. 2003). TNF-α exerts its effects through two
transmembrane receptors: TNF receptor 1 (TNFR1), and TNF receptor 2
(TNFR2). TNFR1 is ubiquitously expressed in most tissues, where TNFR2 is
found mainly on cells of the immune system (Banner, D'Arcy et al. 1993).
Activation of TNFR1 by TNF-α results in a complex series of signalling pathways,
ultimately

leading

to

altered

gene

transcription

in

the

activated

cell

(Parameswaran and Patial 2010). TNFR1 can couple with the adaptor protein
Fas-associated death domain (FADD), which causes progression toward
apoptosis, i.e. programmed cell death (Wallach 1997, Jiang, Wang et al. 2009).
In the context of acute limb ischemia, signals in the TNF-α/TNFR1 pathway have
been found to be upregulated, however it was unknown whether this would
induce apoptosis. In 2009, Jiang et al. induced hind limb ischemia in TNFR1
knockout mice; they found that blocking the TNF-α/TNFR1 pathway prevented
the activation of death-related proteins downstream to TNF-α, and significantly
decreased cell death (Jiang, Wang et al. 2009).
The role of TNFR2 is less clear; however, it has been reported to play a
role in the proliferation of lymphoid cells and it appears to contribute to TNF-αinduced E-selectin, vascular adhesion molecule 1 (VCAM-1), and ICAM-1
expression (Chandrasekharan, Siemionow et al. 2007).
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1.9 CELL DEATH
The activation of TNFR1 is able to signal cell death via its cytoplasmic
death domain in a multitude to cell types (Wajant, Pfizenmaier et al. 2003). TNFα has been shown to initiate cell death by either apoptosis or necroptosis (Wu,
Tan et al. 2011). Apoptosis is a form of genetically programmed cell death,
whereby cell death occurs without the initiation of the inflammatory pathway. It
plays an essential role in embryonic development, tissue homeostasis, immune
function, tumor suppression, infection resistance, and eliminating damaged cells
(Reed 2000, Walsh 2014).
Briefly, apoptosis involves a highly regulated series of events which
involves chromatin condensation, nuclear fragmentation, plasma blebbing, and
cell shrinkage. Cellular fragments are then removed via phagocytosis without
triggering the inflammatory response (Reed 2000). Caspases are a family of
intracellular cysteine proteases critical to triggering apoptosis. Caspases are
present in virtually all cells in their inactive forms, and must be triggered to
assume their active state (Reed 2000, Walsh 2014).
Apoptosis can be triggered by activation of either the extrinsic or intrinsic
pathways. The intrinsic pathway involves the release of cytochrome C from the
mitochondria into the cytoplasm, which then activates a variety of caspases
(Walsh 2014). The extrinsic pathway is initiated by TNF-α binding to TNFR1,
whereby the cytoplasmic death domain recruits other death domain associated
proteins, ultimately inducing caspase activity and apoptosis (Wang, Du et al.
2008, Wu, Tan et al. 2011).
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An additional mechanism of programmed cell death is inducible via

activation of TNFR1 by TNF-α. It has been termed programmed necrosis, or
necroptosis, and occurs independent of caspase activity (Linkermann and Green
2014, Walsh 2014). Necroptosis ensues when there is pan-caspase inhibition,
and the cell is, therefore, unable to undergo apoptosis (Linkermann and Green
2014). It is typically associated with pathological conditions including infection,
ischemia-reperfusion

injury,

stroke,

myocardial

infarction,

pancreatitis,

Alzheimer’s, and inflammatory bowel disease, (Vandenabeele, Galluzzi et al.
2010, Linkermann and Green 2014). The initiation of necroptosis by death
receptors associated with TNFR1 requires the kinase activity of receptorinteracting protein 1 (RIP1), and RIP3. In contrast to apoptosis, necroptosis
involves the disintegration of mitochondrial, lysosomal and plasma membranes
which are then engulfed by macrophages, and elicits an immune response
(Vandenabeele, Galluzzi et al. 2010). Necroptotic cell death has been associated
with the tissue injury that results following I/R. We can deduce from these
findings that this pathway of programmed cell death is also responsible for the
tissue injury associated with CS.

1.10

AIM OF THESIS
The pathophysiology underlying the tissue injury seen in CS remains

largely unknown. It has been well documented in complete I/R literature that
activation of the systemic inflammatory system plays a significant role in the
parenchymal damage associated with reperfusion injury. CS appears to be a low-
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flow ischemic insult; therefore, we have extrapolated from this that the
inflammatory response may contribute to the tissue injury associated with CS.
Leukopenic animal models of CS have demonstrated a significant reduction in
leukocyte activation and tissue injury associated with raised ICP (Lawendy,
Bihari et al. 2015).
The aim of this thesis was, therefore, to investigate the suspected
inflammatory cytokine/chemokine release in response to CS. It has been
previously hypothesized that TNF-α may play a role in the microvascular
dysfunction associated with CS. Therefore, we undertook the evaluation of the
microvascular dysfunction, tissue injury, and inflammatory response following
neutralization of TNF-α at the time of fasciotomy.
We hypothesized that a CS insult is associated with a systemic activation
of the inflammatory response, and that neutralization of TNF-α would decrease
the microvascular dysfunction associated with CS.
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CHAPTER 2: COMPARTMENT SYNDROME AS AN INFLAMMATORY PROCESS

2.1 INTRODUCTION
Compartment syndrome (CS), one of the most devastating consequences of
musculoskeletal trauma, is defined as elevated pressure within a closed
osseofascial compartment (McQueen, Gaston et al. 2000). CS commonly occurs
following fracture of the lower leg; approximately 6% of patients under the age of 35
with a tibial diaphyseal fracture will develop CS (McQueen, Gaston et al. 2000).
CS is a surgical emergency, and the gold standard treatment involves
fasciotomy of the affected limb in order to relieve the raised intra-compartmental
pressure (ICP) (Harvey, Sanders et al. 2012). Despite appropriate and early
fasciotomy, complications of CS include neurologic injury, decreased function of the
extremity, ischemic contractures, infection, loss of limb, and death (Giannoudis,
Nicolopoulos et al. 2002, Dover, Memon et al. 2012, Fry, Wade et al. 2013).
The pathophysiology of CS is only partly understood. Current teachings
propose that raised ICP compromises the microcirculation, which ultimately leads to
decreased oxygen delivery, tissue anoxia, and cell death (Sheridan and Matsen
1975, Whitesides, Haney et al. 1975, Rorabeck and Clarke 1978). In contrast to
complete ischemia, however, CS induces myonecrosis and nerve injury despite
patent blood vessels and a palpable distal pulse (Seddon 1966). CS is, therefore,
considered a ‘low flow’ ischemic state, which results in microvascular hypo-perfusion
that is insufficient to meet the metabolic demands of the tissues (Lawendy, Sanders
et al. 2011). By comparison, complete ischemia, results in macro-vascular

	
  

26	
  

dysfunction, with a loss of distal pulses. Complete ischemia has both a defined
ischemic time and onset of reperfusion once blood flow is restored, while in ‘low flow’
ischemia there is no cessation of blood flow. Therefore, the true onsets of the
ischemic insult, as well as the onset of reperfusion, are unknown.
The initiation of the inflammatory response has been well delineated in
complete ischemia-reperfusion injury, as seen primarily in organ transplant and revascularization procedures (Forbes, Harris et al. 1996, Harris and Skalak 1996). CS
falls within the spectrum of ischemia-reperfusion injury. Therefore, we have
postulated that the ongoing ischemia-reperfusion injury, associated with CS, will also
cause an early and concurrent initiation of the systemic inflammatory cascade.
A previous study by our group had assessed CS-induced microvascular
dysfunction, tissue injury, and leukocyte activation in a leukopenic rat model
(Lawendy et al. 2015). We demonstrated that leukopenia provided significant
protection against CS-induced muscle injury, concurrent with a significant reduction
in leukocyte activation. It did not, however, provide any protection against the
microvascular dysfunction associated with CS.
We hypothesized that the injury seen as a result of CS is secondary to both
ischemia and the early initiation of the inflammatory cascade, with ongoing and
simultaneous reperfusion, thereby inducing the systemic inflammatory response.
The purpose of our study was to examine the suspected inflammatory
cytokine/chemokine release in response to CS.
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2.2 METHODS
2.2.1 Animal Handling and Care
Male Wistar rats were utilized for these experiments. Animals had access to
food and water ad libitum. Animal housing, care, and associated protocols were
conducted in agreement with the Canadian Council on Animal Care. The Animal Use
Subcommittee at The University of Western Ontario approved the animal protocol for
this study.

2.2.2 Experimental Protocol
Five rats (body weight 180 - 250g) were anesthetized with inhalational
isoflurane (5% induction, 2% maintenance, titrated as needed to maintain an
adequate level of general anesthesia) in a 1:1 O2:N2 mixture. The left carotid artery
was cannulated for continuous blood pressure monitoring, blood sampling, and fluid
replacement. A rectal probe was inserted to monitor core body temperature, which
was adjusted using a heat lamp, as needed. We used a normotensive and
normothermic model of CS, where the mean arterial blood pressure was maintained
at 100mmHg, and core body temperature at 37°C.

2.2.3 Compartment Syndrome
Isotonic saline was infused into the anterior compartment of the right hind
limb via a 24-gauge catheter in order to elevate the ICP, as previously described
(Lawendy, Sanders et al. 2011). The ICP was measured by an electronic
compartmental pressure monitoring system (Synthes USA, Paoli, PA), which was
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inserted into the posterior compartment through a 14-gauge angiocatheter (Figure
2.1). The ICP was maintained at 30-40mmHg for 120 minutes; this was followed by
fasciotomy and then 45 minutes of reperfusion.

2.2.4 Blood Sampling
Blood samples were collected from the indwelling carotid line. At each
sampling time, 0.3ml of blood was extracted and replaced with an equal volume of
normal saline. Blood sampling was done as follows: (1) at the time of carotid artery
cannulation, for baseline levels; (2) after 1hr of CS; (3) 2hrs of CS; following (4) 10-;
(5) 20-; (6) 30-; and (7) 45-mintues of reperfusion. All blood samples were stored on
ice during the surgical procedure and then centrifuged at 1200xg for 15min at room
temperature. Serum was collected and placed into clean micro-centrifuge tubes and
stored at -800C.

2.2.5 Cytokines/Chemokines Sampled
Serum samples were diluted at 1:5 dilution, as per the manufacturer’s
instructions, and run on a 24-plex xMAP Luminex assay (Millipore, Billerica MA) for
simultaneous testing of the following pro-inflammatory cytokines/chemokines: Tumor
Necrosis Factor (TNF)-α, Interleukin (IL)-1α, IL-1β, IL-2, IL-5, IL-12p70, IL-13, IL-17,
IL-18, Interferon Gamma (IFN-Υ), Eotaxin, Interferon Gamma-Induced Protein (IP)10, Macrophage Inflammatory Protein (MIP)-1α, Leptin, Monocyte Chemotactic
Protein (MCP)-1, Growth Regulated Oncogene/Keratinocyte-Derived Chemokine
(GRO/KC), RANTES.
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Experimental Set-Up for Rat Model of CS. Rat was anesthetized with
isoflurane, and left carotid artery cannulated for blood pressure
monitoring. Isotonic saline was infused into the anterior compartment
to raise ICP, with continuous ICP monitoring via 14G catheter in the
posterior compartment.
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White blood cell growth factors Granulocyte Macrophage-Colony Stimulating Factor
(GM-CSF) and Granulocyte-Colony Stimulating Factor (G-CSF) were tested, along
with the angiogenic cytokine Vascular Endothelial Growth Factor (VEGF).
Additionally, a number of anti-inflammatory cytokines were tested and included IL-4,
IL-9, IL-10, as well as IL-6, which can be both pro- and anti-inflammatory.

2.2.6 Statistical Analysis
The numbers were expressed as means±SEM. Repeated measures one-way
analysis of variance testing (ANOVA) was used to compare each sample within the
time course to its baseline levels, with Newman-Keuls multiple comparison post hoc
test where appropriate (GraphPad Prism V5.0, San Diego, CA). Sample size
calculation was performed using StatMate (GraphPad Software Inc., San Diego,
CA), with power set at 85%. Statistical significance was defined as p<0.05.

2.3 RESULTS
2.3.1 Detectable Cytokines/Chemokines
Of the 24 cytokines/chemokines sampled, 14 were detectable using xMAP
Luminex technology. These included TNF-α, IL-1α, IL-1β, IL-12p70, IL-13, IL-18,
IFN-γ, Eotaxin, MIP-1α, Leptin, MCP-1, GRO/KC, IL-10, and IL -6.
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2.3.2 Significantly Elevated Cytokines/Chemokines
Six of the 14 cytokines/chemokines that were detectable were significantly
elevated from their baseline levels: TNF-α significantly increased across all time
points, from 32.1±2.6pg/ml at baseline to 226.3±31.0pg/ml, 335.7±64.7pg/ml,
317.7±68.5pg/ml, 338.4±85.5pg/ml, 403.3±131.5pg/ml, and 798.7±370.7pg/ml at 1hr
of CS, 2hrs of CS, 10min, 20min, 30min, and 45min of reperfusion, respectively
(p<0.05) (Figure 2.2).
IL-1β levels were significantly elevated from the baseline of 26.7±26.7pg/ml to
97.7±32.1pg/ml, 141.3±13.1pg/ml, 102.2±22.1pg/ml, and 119.9±17.6pg/ml at 1hr of
CS, 2hrs of CS, 10, and 20 minutes of reperfusion, respectively (p<0.05). By 30 and
45minutes of reperfusion, systemic IL-1β levels returned to the baseline levels of
46.0±46.0pg/ml and 61.2±31.7pg/ml, respectively (Figure 2.3).
GRO/KC levels were significantly elevated from 990.2±190.8pg/ml at
baseline, to 27217.0±6939.0pg/ml, 29073.0±7169.0pg/ml, 31115.0±7961.0pg/ml,
32494.0±5763.0pg/ml, and 35529.0±2624.0pg/ml at 2hrs of CS, 10, 20, 30, and 45
minutes of reperfusion, respectively (p<0.05). After 1hr of CS, GRO/KC level was
2985.0±1172.0pg/ml (n.s.) (Figure 2.4).
MCP-1 levels were significantly elevated from the baseline level of
313.4±31.4pg/ml

to

698.8±300.6pg/ml,

803.4±374.6pg/ml,

926.0±549.6pg/ml,

849.7±395.3pg/ml, and 778.2±289.4pg/ml after 2hrs of CS, 10, 20, 30, and 45
minutes of reperfusion, respectively (p<0.05). After 1hr of CS, MCP-1 level was
305.0±34.0pg/ml (n.s.) (Figure 2.5).
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MIP-1α levels were significantly elevated across all time points, from 0.0

pg/ml

at

baseline,

to

41.9±34.3pg/ml,

84.8±36.6pg/ml,

68.9

±14.5pg/ml,

81.4±21.3pg/ml, 103.3±24.9pg/ml, and 131.1±29.3pg/ml after 1hr of CS, 2hrs of CS,
10, 20, 30, and 45 minutes of reperfusion, respectively (p<0.05) (Figure 2.6).
IL-10 levels were significantly elevated across all time points, from the
baseline

of

68.4±68.4pg/ml

to

676.9±358.7pg/ml,

1138.0±372.3pg/ml,

898.4±225.8pg/ml, 591.7±225.2pg/ml, 727.0±180.5pg/ml, and 1023.0±97.3pg/ml
after 1hr of CS, 2hrs of CS, 10, 20, 30, and 45 minutes of reperfusion, respectively
(p<0.05) (Fig 2.7).

2.4 DISCUSSION
CS, a complication of muscle trauma, poses a particular challenge. The
pathophysiological mechanisms of CS are complex and not fully understood. The
purpose of this study was to determine if the low-flow ischemia associated with CS
would result in the systemic activation of the inflammatory response.

2.4.1 Systemic Inflammatory Response
Acute inflammation is characterized by the activation of circulating leukocytes,
whereby activation results in leukocyte rolling and adhesion. Activated leukocytes
produce reactive oxygen species, and release cytokines and chemokines, as a
consequence of the reintroduction of oxygen into ischemic tissue (Harkin, Barros
D'sa A et al. 2001). The generation of reactive oxygen species ultimately triggers
cellular apoptosis and necrosis (Schlag, Harris et al. 2001).
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Time Course of TNF-α Expression in Rat Model of CS. CS induced
a significant increase in systemic TNF-α after 1hr and 2hrs of raised
ICP, and at each time point measured during reperfusion. Peak TNF-α
levels were seen after 45-minutes of reperfusion with a 25-fold
increase from baseline (*p<0.05 from baseline, repeated measures
one-way ANOVA).
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Time Course of IL-1β Expression in Rat Model of CS. CS induced a
significant increase in systemic IL-1β after 1hr and 2hrs of raised ICP,
and through 20 minutes of reperfusion. Levels were no longer
significantly elevated from baseline after 30 or 45 minutes of
reperfusion (*p<0.05, repeated measures one-way ANOVA).
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Time Course of GRO/KC Expression in Rat Model of CS. CS
induced a significant increase in systemic GRO/KC after 2hrs of raised
ICP, and at each time point measured throughout reperfusion (*p<0.05,
repeated measures one-way ANOVA).
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Time Course of MCP-1 Expression in Rat Model of CS. CS induced
a significant increase in systemic MCP-1 after 2hrs of raised ICP, and
at each time point measured throughout the reperfusion period
(*p<0.05, repeated measures one-way ANOVA).
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Time Course of MIP-1α Expression in Rat Model of CS. CS induced
a significant increase in systemic MIP-1α after 1hr of raised ICP, and at
each time point measured throughout the 45 minutes reperfusion
period (*p<0.05, repeated measures one-way ANOVA).
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Time Course of IL-10 Expression in Rat Model of CS. CS induced a
significant increase in systemic IL-10 after 1hr of CS, and at each time
point measured throughout the 45-minute reperfusion period (*p<0.05,
repeated measures one-way ANOVA).
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It has been well documented that revascularization following complete
ischemia results in the initiation of acute inflammation (Gute, Ishida et al. 1998, Lum
and Roebuck 2001, Schlag, Harris et al. 2001). Using a model of complete hind limb
ischemia, animals rendered neutropenic prior to the onset of ischemia had a delay in
the onset of muscle injury, and a decrease in the magnitude of injury seen (Forbes,
Harris et al. 1996). Additionally, an earlier and more rapid onset of leukocyte
activation was shown in a rodent model of partial ischemia when compared to
complete ischemia (Heppenstall, Scott et al. 1986, Forbes, Harris et al. 1996,
Lakshminarayanan, Lewallen et al. 2001).

2.4.2 Systemic Cytokine/Chemokine Release
Cytokines are intercellular signaling peptides released from stimulated
leukocytes, which induce the production of other cytokines and cell surface
receptors through their effects on gene transcription (Cannon 2000, Grivennikov,
Kuprash et al. 2006).
Chemokines are a family of chemotactic cytokines, which recruit monocytes,
neutrophils, and lymphocytes to sites of injury and inflammation. Chemotaxis is
induced through the activation of G-protein-coupled receptors, and the receptors that
a given leukocyte expresses usually determines the chemokines to which it will
respond (Charo and Taubman 2004). Chemokines are secreted by a variety of cell
types, including leukocytes, fibroblasts, and endothelial cells (Roebuck, Carpenter et
al. 1999).
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While an increasing amount of literature exists to suggest that the initiation of

the systemic inflammatory response plays a role in the myonecrosis associated with
CS, no study to date has directly measured the cytokine/chemokine release induced
by CS. A normothermic and normotensive model of CS was used in order to remove
the possibility of a systemic inflammatory response secondary to hypoperfusion and
shock.
Our study has confirmed that CS induces a systemic cytokine/chemokine
release. Of the 24 cytokines/chemokines measured, 14 were detectable. Of the 14
detected, 12 were pro-inflammatory, 1 was anti-inflammatory, and 1 had both a proand an anti-inflammatory effect.
Six of the 14 cytokines/chemokines that were detectable were significantly
elevated from their baseline levels after 2hrs of CS. These include TNF-α, IL-1β,
GRO/KC, MCP-1, MIP-1α, and IL-10.
TNF-α is a pro-inflammatory cytokine, and one of the first cytokines released
with the initiation of inflammation. It serves as a chemoattractant for neutrophils, upregulation of downstream cytokine/chemokine production, and it promotes the
expression of adhesion molecules (Ascer, Gennaro et al. 1992, Yi and Ulich 1992,
Seekamp, Warren et al. 1993, Krishnadasan, Naidu et al. 2003, Zhang, Hu et al.
2005).
IL-1β is a pro-inflammatory cytokine, and it is produced by activated
macrophages. It is involved in multiple cellular functions including cell proliferation,
differentiation, and apoptosis (Gao, Madi et al. 2014).
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GRO/KC is a pro-inflammatory cytokine, and it is produced by macrophages

and neutrophils. It serves to induce neutrophil chemotaxis. It is also seen in high
levels in chronic inflammatory states such as chronic obstructive pulmonary disease
(COPD) and rheumatoid arthritis (Bechara, Chai et al. 2007).
MCP-1 is a pro-inflammatory cytokine whose primary role is to recruit
monocytes/macrophages to sites of injury (Shireman, Contreras-Shannon et al.
2007). MCP-1 is secreted by macrophages that have been induced by proinflammatory cytokines including TNF-α and IL-1β, and has been shown to play a
role in angiogenesis following an ischemic stress (Lakshminarayanan, Lewallen et
al. 2001). Additionally, MCP-1 exerts its effects by binding to leukocytes, and
targeting them for activation (Yadav, Saini et al. 2010).
MIP-1α is a pro-inflammatory cytokine and is produced by macrophages,
lymphocytes, and dendritic cells. It is chemotactic for cells of the monocyte lineage
as well as for lymphocytes. Additionally it appears to inhibit the proliferation of
hematopoietic stem cells (Cook 1996).
IL-10 is an anti-inflammatory cytokine, and is produced by monocytes,
macrophages, dendritic cells, and lymphocytes. It is an inhibitor of antigen
presentation, and prevents the differentiation of monocyte precursors, and the
maturation of dendritic cells (Mosser and Zhang 2008).
The results of our study have confirmed that CS induces a substantial, and
predominantly

pro-inflammatory

response.

The

initiation

of

the

systemic

inflammatory response should, therefore, be considered in the pathophysiology of
CS. The systemic inflammatory response is complex and redundant therefore, the
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exact mechanism of initiation and the interplay between cytokines and chemokines
in CS needs to be further delineated.
To our knowledge, this is the first study that directly confirms CS as an
inflammatory process. The results are the beginning step, in order to extrapolate the
mechanisms by which injury occurs. The identification of specific mediators could
potentially serve as pharmacologic targets in future studies in an attempt to
decrease the devastating consequences of CS.
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CHAPTER 3: SYSTEMIC TNF-α RELEASE CONTRIBUTES TO
MICROVASCULAR DYSFUNCTION AND TISSUE INJURY IN
COMPARTMENT SYNDROME

3.1 INTRODUCTION
There are few more devastating complications of musculoskeletal trauma
than compartment syndrome (CS). CS is caused by increased pressure within a
closed osseofascial compartment, the most common etiology being fracture of
the lower extremity (Matsen 1975, Whitesides, Haney et al. 1975, Whitesides,
Haney et al. 1975, Mubarak, Owen et al. 1978, Rorabeck and Clarke 1978,
Matsen, Winquist et al. 1980, Rorabeck 1984, Tornetta and Templeman 1997).
Increased

intra-compartmental

pressure

(ICP)

leads

to

microvascular

dysfunction, which results in limited oxygen and nutrient delivery to the tissues.
Cellular anoxia eventually leads to myonecrosis, the sequelae of which include
permanent functional impairment, loss of limb, and even death (Sheridan and
Matsen 1975, Whitesides, Haney et al. 1975, Heckman, Whitesides et al. 1994,
Fry, Wade et al. 2013).
In contrast to complete ischemia, CS causes myonecrosis despite vessels
being patent: it has been demonstrated that ischemic changes occur even in the
presence of a distal pulse (Seddon 1966). This clinical paradox suggests that the
pathophysiology of CS is more complex than previously thought.
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The use of intravital video microscopy (IVVM) in animal models of

complete limb ischemia and reperfusion (I/R) have shown that activated
leukocytes directly impair capillary perfusion, and contribute to the parenchymal
injury occurring with the onset of reperfusion (Forbes, Carson et al. 1995,
Forbes, Harris et al. 1996, Harris and Skalak 1996). Previous studies by our
group have shown a dramatic increase in leukocyte activation in the postcapillary venules of skeletal muscle following a CS insult (Lawendy, Sanders et
al. 2011). It has been extrapolated from this data that CS appears to induce a
low-flow ischemic state, and due to the patent macro-circulatory system there is,
therefore, an ongoing low-flow ischemia and reperfusion injury occurring.
The initiation of the inflammatory pathway has been well described in the
I/R literature, whereby activated leukocytes impair capillary perfusion and also
result in parenchymal damage following reperfusion (Forbes, Carson et al. 1995,
Forbes, Harris et al. 1996, Harris and Skalak 1996). Within the first hour of
reperfusion, a peak in the pro-inflammatory cytokine, tumor necrosis factor alpha
(TNF-α) has been reported, and it is believed to be a driving force of
inflammation following a complete ischemic insult (Caty, Guice et al. 1990, Brock,
Lawlor et al. 1999, Krishnadasan, Naidu et al. 2003). TNF-α appears to act as a
chemoattractant

for

neutrophils,

causes

up-regulation

of

downstream

cytokine/chemokine production, and promotes the expression of adhesion
molecules (Ascer, Gennaro et al. 1992, Yi and Ulich 1992, Seekamp, Warren et
al. 1993, Krishnadasan, Naidu et al. 2003, Zhang, Hu et al. 2005).
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It has been hypothesized that TNF-α may act as an important driving force

of CS pathophysiology. Therefore, the purpose of this study was to evaluate the
microvascular dysfunction, tissue injury, and inflammatory response following the
neutralization of TNF-α at the time of fasciotomy, in an animal model of CS.

3.2 METHODS
3.2.1 Animal Handling and Care
Male Wistar rats were utilized for these experiments. Animals had access
to food and water ad libitum. Animal housing, care, and associated protocols
were conducted in agreement with the Canadian Council on Animal Care. The
animal protocol for this study was approved by the Animal Use Subcommittee at
The University of Western Ontario.

3.2.2 Experimental Protocol
A total of twelve male Wistar rats (body weight 180 - 250g) were randomly
assigned into three groups: (1) sham (n= 4), (2) CS (with isotype control) (n=4),
and (3) CS with TNF-α neutralization (CS+TNF-α) (n=4). Animals were
anesthetized with inhalational isoflurane (5% induction, 2% maintenance, titrated
as needed to maintain an adequate level of general anesthesia) in a 1:1 O2:N2
mixture. The left carotid artery was cannulated for continuous blood pressure
monitoring, blood sampling, and fluid replacement. A rectal probe was inserted to
monitor core body temperature, which was adjusted using a heat lamp, as
needed. A normotensive and normothermic model of CS was used, where the
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mean arterial blood pressure was maintained at 100mmHg, and core body
temperature at 37°C.

3.2.3 Compartment Syndrome
Isotonic saline was infused into the anterior compartment of the right hind
limb via a 24-gauge catheter in order to elevate the ICP, as previously described
(Lawendy, Sanders et al. 2011). The ICP was measured by an electronic
compartmental pressure monitoring system (Synthes USA, Paoli, PA), which was
inserted through a 14-gauge angiocatheter into the posterior compartment
(Figure 2.1). The ICP was maintained at 30-40mmHg for 2 hours; this was
followed by fasciotomy and 45 minutes of reperfusion.
Animals that underwent CS followed by isotype control for TNF-α were
administered 0.3ml Armenian hamster IgG (3.5µg of IgG per 200g body weight,
IV, eBioscience, SanDiego, CA) at the time of fasciotomy, while those in the
CS+TNF-α neutralization group were administered 0.3ml TNF-α neutralizing
antibody (3.5µg TNF-α neutralizing antibody per 200g body weight, IV,
eBioscience, SanDiego, CA) at the time of fasciotomy.
Sham animals underwent the same procedure as those in the CS groups;
however the ICP was kept at the baseline level of 0mm Hg for 2 hours, followed
by fasciotomy and 45 minutes of reperfusion.
Intravital video microscopy (IVVM) was then performed on all animals to
assess microvascular dysfunction, leukocyte activation and the parenchymal
injury to the extensor digitorum longus (EDL) muscle.
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3.2.4 Blood Sampling
Blood samples were collected via an indwelling carotid line. At each
sampling time, approximately 0.3ml of blood was extracted and replaced with an
equal volume of normal saline. Blood sampling was done as follows: (1) at the
time of carotid artery cannulation, for baseline levels; (2) after 2 hours of CS, just
prior to fasciotomy/antibody injection; and (3) following 45-mintues of reperfusion.
All blood samples were allowed to coagulate on ice during the surgical procedure
and then centrifuged at 1200xg for 15min at room temperature. Serum was
collected and placed into clean micro-centrifuge tubes and stored at -80°C.

3.2.5 Intavital Video Microscopy (IVVM)
Following fasciotomy, the EDL muscle was prepared for IVVM, as
previously described (Potter, Dietrich et al. 1993, Forbes, Carson et al. 1995,
Manjoo, Sanders et al. 2010, Lawendy, Sanders et al. 2011). The animal was
then transferred onto the stage of an inverted microscope (Nikon, Nikon
Instruments, Inc., Mississauga, Ontario, Canada) and the EDL muscle was
reflected into a saline bath containing 5µg/ml each of the fluorescent vital dyes
bisbenzimide (BB; excitation wavelength (Ex) 343 nm, emission wavelength (Em)
483 nm) and ethidium bromide (EB; Ex 482 nm, Em 616 nm). BB stains nuclei of
all cells while EB stains the nuclei of only those cells with damaged cell
membranes. The EB/BB ratio, therefore, provides a measure of tissue injury.
Microvascular perfusion and leukocytes within the post capillary venules
were recorded by translumination with 20x and 40x objectives respectively, in
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five adjacent fields of view, and captured into a computer for offline video
analysis. Fluorescence microscopy was used to visualize the BB- and EBlabelled cells from these same fields of view. At the conclusion of the experiment,
the rats were euthanized by an overdose of anesthetic agent.

3.2.6 Offline Video Analysis
Capillary perfusion was assessed by counting the number of continuously
perfused (CPC), intermittently perfused (IPC), and non-perfused (NPC)
capillaries crossing three parallel lines drawn perpendicular to the capillary axis
on the video monitor, and was expressed as a percentage (%) of total capillaries.
Tissue injury was assessed by counting the number of EB- and BBlabelled nuclei, and expressed as EB/BB ratio.
Leukocyte activation was assessed by counting the number of rolling and
adherent leukocytes in post-capillary venules, and expressed as cells per unit
area (i.e. 1000 µm2). Venular area was measured using ImageJ software (NIH,
Bethesda, Maryland). A leukocyte was considered adherent if it remained
stationary for at least 30 seconds and rolling if it remained in contact with the wall
of the vessel but did not remain stationary.

3.2.7 Measurement of Serum TNF-α
To evaluate the effect of CS on TNF-α production, and to confirm TNF-α
neutralisation, serum levels of TNF-α were assessed in all animals using
enzyme-linked immunosorbent assay (ELISA) kit (Pierce Biotechnology, c/o
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Thermo Scientific, Rockford, IL), as per manufacturer’s instructions. The assay
was sensitive to less than 5pg/ml.

3.2.8 Statistical Analysis
One-way analysis of variance (ANOVA) was used to compare the degree
of perfusion, tissue injury and leukocyte activation (both adherence and rolling).
Repeated measures two-way ANOVA was used to compare the serum levels of
TNF-α. Newman-Keuls multiple comparison post hoc test was used where
appropriate (GraphPad Prism V5.0, San Diego, CA). Sample size calculation was
performed using StatMate (GraphPad Software Inc., San Diego, CA), with power
set at 85%. Statistical significance was defined as a p-value <0.05.

3.3 RESULTS
3.3.1 Microvascular Perfusion
The perfusion profile seen in the sham group demonstrated predominately
continuously perfused capillaries. The perfusion profile of both the CS and the
CS+TNF-α neutralizing groups demonstrated a shift toward IPC and NPC (Figure
3.1).
The number of CPC decreased from 75.08±2.3% in the sham group to
30.66±3.6%, and 35.7±3.5% in the CS and CS+TNF-α neutralizing groups,
respectively (p<0.0001). There was no significant difference in CPC between the
CS and CS+TNF-α neutralizing groups.
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Figure 3.1. The Effect of Elevated ICP on Microvascular Perfusion in Rat
Model of CS. CS resulted in a significant microvascular perfusion
deficit. Neutralization of TNF-α at fasciotomy did not restore the
microvascular perfusion (*p<0.05 from Sham; one-way ANOVA).
CPC, continuously-perfused capillaries; IPC, intermittently-perfused
capillaries; NPC, non-perfused capillaries.
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The number of IPC increased from 10.76±1.5% in sham to 19.08±1.3%,

and 25.09±2.7% in the CS and CS+TNF-α neutralizing groups, respectively
(p<0.001). The number of IPC in the CS+TNF-α neutralizing group was
significantly higher than that in CS group (p<0.05).
The number of NPC increased from 14.18±1.4% in sham to 50.27±2.6%,
and 39.19±2.8% in the CS and CS+TNF-α neutralizing groups, respectively
(p<0.0001). The number of NPC in the CS+TNF-α neutralizing group was
significantly lower as compared to the CS group (p<0.05).

3.3.2 Tissue Injury
Tissue injury significantly increased following elevation of ICP, from
0.04±0.02 in sham to 0.33±0.04 in CS group (p<0.001) (Figure 3.2).
Administration of TNF-α neutralizing antibody resulted in a significant decrease
when compared to CS group, to 0.21±0.04 (p<0.05).

3.3.3 Leukocyte Activation
Elevation of ICP resulted in a significant increase in leukocyte adherence,
from 1.7±0.4 leukocytes/30s/1000µm2 to 14.1±1.6 leukocytes/30s/1000µm2 in CS
group (p<0.05) (Figure 3.3). Administration of TNF-α neutralizing antibody
produced a significant decrease to 0.9±0.2 adherent leukocytes/30s/1000µm2
(p<0.05).
Elevation of ICP resulted in an increase in leukocyte rolling, from 2.1±0.8
leukocytes/30s/1000µm2 in sham to 9.8±3.2 leukocytes/30s/1000µm2 in CS
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Figure 3.2. Tissue Injury In a Rat Model of CS. Elevation of ICP resulted in a
significant increase in tissue injury. Administration of a TNF-α
neutralizing antibody at fasciotomy significantly diminished tissue
injury (*p<0.05 from Sham, #p<0.05 from CS; one-way ANOVA).
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Leukocyte Activation (Adhesion) in a Rat Model of CS.
Elevation of ICP resulted in an increase in adherent leukocytes.
Administration of TNF-α neutralizing antibody at fasciotomy blocked
leukocyte adhesion (*p<0.0001 from Sham; one-way ANOVA).
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Leukocyte Activation (Rolling) in a Rat Model of CS. Elevation
of ICP resulted in a significant increase in leukocyte rolling.
Administration of TNF-α neutralizing antibody at fasciotomy
resulted in leukocyte rolling returning to the baseline level
(*p<0.0001 from Sham; one-way ANOVA).
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group (p<0.05) (Figure 3.4). Administration of TNF-α neutralizing antibody
resulted in a significant decrease to 2.4±1.0 leukocytes/30s/1000µm2 (p<0.05).

3.3.4 Serum TNF-α
Serum TNF-α levels in the sham animals showed no significant changes
from the baseline level of 12.1±6.9pg/ml: serum levels of TNF-α at 2hr CS and
45min reperfusion were 14.8±3.8pg/ml, and 12.6±5.9pg/ml respectively (p=0.357,
n.s.) (Figure 3.5).
Elevation of ICP resulted in a significant increase in serum TNF-α, from
16.1±4.8pg/ml at baseline to 1496.0±152.6pg/ml just prior to fasciotomy (p<0.05)
(Figure 3.5). TNF-α level remained significantly elevated, at 2391.0±445.7pg/ml
after 45 minutes of reperfusion (p<0.05). Administration of TNF-α neutralizing
antibody at fasciotomy resulted in a complete inhibition of TNF- α, to 0pg/ml
(p<0.05).

3.4 DISCUSSION
The underlying pathophysiological mechanism of the tissue injury
associated with acute compartment syndrome remains largely unknown.
Previous work by our group, and others, has begun to recognize the role of the
inflammatory pathway in microvascular compromise, and tissue injury, seen in
CS (Manjoo, Sanders et al. 2010, Lawendy, Sanders et al. 2011, Lawendy, Bihari
et al. 2015). The immune system is amenable to modulation, and, therefore,
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Figure 3.5. Serum TNF-α Levels in a Rat Model of CS. Elevation of ICP
resulted in a significant increase in systemic TNF-α, which
continued to rise during the 45-minute reperfusion period (red line).
Injection of TNF-α neutralizing antibody at fasciotomy resulted in a
complete inhibition of serum TNF-α levels (blue dotted line).
Systemic TNF-α levels remained constant in sham animals (black
line) (*p<0.05 from baseline, †p<0.05 from CS+TNF-α group;
repeated measures two-way ANOVA).
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potentially represents a therapeutic target in order to decrease the tissue injury
associated with CS. We chose to target TNF-α as it has been shown to be
acutely elevated in complete I/R injury (Caty, Guice et al. 1990, Brock, Lawlor et
al. 1999).
Microvascular perfusion, under normal physiological conditions, is
primarily that of continuous blood flow. CS causes a shift in perfusion toward
intermittently perfused and non-perfused capillaries. An ischemic environment
within the affected capillary bed ensues, resulting in decreased nutrient and gas
exchange. There remains, however, continuous perfusion within a small portion
of the capillaries, creating a low-flow ischemic environment in contrast to a
complete ischemic state.
The neutralization of TNF-α essentially had no effect on the microvascular
perfusion profile seen in CS (Figure 3.1). Tempering the inflammatory response
did not, therefore, provide protection in restoring microvascular perfusion in the
face of elevated compartment pressures. These results are in keeping with the
previous work, whereby a leukocyte-deplete animal model was not shown to be
protective in restoring the microvascular perfusion following a CS insult
(Lawendy, Bihari et al. 2015). A distinction with complete I/R must again be
highlighted: microvascular dysfunction was prevented, and parenchymal injury
was reduced in a leukocyte deplete I/R model (Forbes, Harris et al. 1996). This
data further corroborates that the microvascular dysfunction associated with
compartment syndrome has a distinct pathophysiology compared to that of
complete ischemia-reperfusion.
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The results of our study confirm that CS induces a systemic inflammatory

response. Elevation of ICP for 2 hours resulted in a significant increase in serum
TNF-α, coupled with the recruitment of activated leukocytes, and arrest of
leukocytes, observed under live microscopy (Figure 3.5). Blocking the
inflammatory response post-fasciotomy, through the administration of TNF-α
neutralizing antibody, significantly decreased leukocyte activation, as evidenced
by a decrease in both rolling and adherent leukocytes within the post-capillary
venules (p<0.05 and p<0.0001 respectively) (Figure 3.3 and Figure 3.4).
Activated leukocytes are known to produce reactive oxygen species and
proteolytic enzymes; this results in an increased vascular permeability and tissue
edema, cellular injury, and raised interstitial pressure. Combined, the effects may
exacerbate perfusion dysfunction in the microvascular bed.
In this study, elevation of ICP resulted in a significant increase in the
number of EB-labelled nuclei (i.e. tissue injury). Neutralization of TNF-α led to a
significant relative reduction of approximately 36% in tissue injury (Figure 3.2).
This data confirms that TNF-α plays at least some role in the inflammatory
response observed in a CS insult. In a leukocyte-deplete animal model of CS,
tissue injury was reduced by more than 50%, implying that there are also other
cytokines/chemokines involved in the pathophysiology of CS (Lawendy, Bihari et
al. 2015).
Leukocyte activation within the post capillary venules appears to play a
role in producing the tissue injury observed in CS, without directly affecting the
perfusion profile of the microvascular beds. In the early phase of CS, at least,
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TNF-α plays a role in the tissue injury associated with CS. Neutralizing TNF-α in
isolation had less of an effect on reducing tissue injury in comparison to a
completely leukocyte deplete animal model, again suggesting a role for also
other cytokines/chemokines in the pathophysiology of CS (Lawendy, Bihari et al.
2015).
The study validates immune modulation as a potential therapeutic target in
order to diminish the parenchymal injury associated with CS. While TNF-α is only
one of many cytokines/chemokines in a complex and redundant system, its
neutralization did result in a significant decrease in tissue injury. Continued
investigation is still required, as this is only one small piece of a complex
pathophysiological mechanism.
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CHAPTER 4: GENERAL DISCUSSION AND CONCLUSIONS

4.1 OVERVIEW OF RESULTS
4.1.1 Pathophysiology of Compartment Syndrome
Compartment syndrome (CS) remains one of the most devastating
complications of musculoskeletal trauma. It occurs secondary to elevated
pressure within a closed osseofascial compartment, and is both a limb and lifethreatening condition (McQueen, Gaston et al. 2000, Hayakawa, Aldington et al.
2009). Despite being a recognized complication of trauma since Richard von
Volkmann’s description of ischemic contracture in the upper limb of children in
1881, to date the underlying pathophysiological mechanism remains largely
unknown (von Volkmann 1881).
Raised intra-compartmental pressure (ICP) is the initial insult seen in CS,
which then leads to microvascular dysfunction, hypo-perfusion of the tissues, and
ultimately cellular anoxia and cell death (Sheridan and Matsen 1975, Whitesides,
Haney et al. 1975, Rorabeck and Clarke 1978, Harvey, Sanders et al. 2012).
There are a few important distinctions that must be drawn between CS and
complete ischemia-reperfusion (I/R) injury: CS causes tissue necrosis despite a
patent macrocirculatory system, where ischemic tissue injury occurs in the face
of a palpable distal pulse (Seddon 1966), and a CS insult is more injurious than a
complete ischemic insult of the same duration (Heppenstall, Scott et al. 1986).
These findings suggest that the pathophysiology of CS involves a low-flow
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ischemic state, is more complex than previously understood, and is distinct from
that of complete I/R injury.

4.1.2 Compartment Syndrome as Low-Flow Ischemia
Under normal conditions, microvascular perfusion exhibits predominantly
continuously perfused capillaries (CPC). Raised ICP has been shown to cause a
shift in perfusion toward intermittently perfused capillaries (IPC), and nonperfused capillaries (NPC) (Lawendy, Sanders et al. 2011, Lawendy, Bihari et al.
2015). The presence of CPC in the same muscle bed as IPC and NPC suggests
that CS induces a low-flow ischemic state, as there is some degree of continuous
perfusion still present. Ischemia ensues as a consequence of inefficient nutrient
and gas exchange to meet the metabolic demands of the tissue, despite some
continuous oxygen delivery (Lawendy, Sanders et al. 2011). We believe that this
ongoing perfusion in the face of an essentially ischemic tissue bed is analogous
to the reperfusion injury associated with complete I/R injury. The presence of
oxygen in ischemic tissue results in the generation of reactive oxygen
metabolites, the initiation of an acute inflammatory state, and triggers cellular
death via apoptosis and necroptosis (Gute, Ishida et al. 1998, Lum and Roebuck
2001). This pattern of tissue injury is, however, distinct from that of complete I/R,
which has defined phases of injury (ischemia, then reperfusion). We believe the
low-flow ischemic state associated with CS initiates an early and continuous
reperfusion injury, which not only persists for the duration of the raised ICP, but is
exacerbated by fasciotomy and the restitution of blood flow to the capillary beds.
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Heppenstall et al (1986) have demonstrated, in a canine model, that a CS insult
is more injurious than a complete ischemic insult of the same duration, further
corroborating our theory that CS incudes an early and continuous state of
reperfusion injury.
The first aim of this thesis was to confirm that CS induces the systemic
inflammatory response, and to examine the specific cytokines/chemokines
released as a result. A further focus of this thesis was to evaluate the
microvascular dysfunction, tissue injury, and inflammatory response following the
neutralization of TNF-α at the time of fasciotomy. The background for these
studies has been primarily extrapolated from I/R literature and, more recently,
from studies by our group; thus the role of inflammation in CS-induced tissue
injury is beginning to be recognized.

4.1.3 Compartment Syndrome as an Inflammatory Process
The study was designed to confirm that CS is associated with the initiation
of a systemic inflammatory response, and to examine the suspected
inflammatory cytokine/chemokine release in response to CS. The initiation of the
inflammatory response has been well described following complete I/R injury,
however, to our knowledge, had not been studied to-date in CS. The use of IVVM
imaging

of

the

capillaries

following

CS

has

demonstrated

significant

microvascular dysfunction, concurrent with a significant increase in leukocyte
activation in the post-capillary venules of skeletal muscle (Lawendy, Bihari et al.
2015). These findings suggested that CS induces a pro-inflammatory
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environment; however, the specific cytokines/chemokines involved remained
unknown. Following a complete I/R injury, activated leukocytes in the postcapillary venules have been shown to directly inhibit capillary perfusion, cause
direct parenchymal damage following the onset of reperfusion, increase vascular
permeability, and increase tissue edema (Kurose, Anderson et al. 1994, Forbes,
Harris et al. 1996, Harris and Skalak 1996).
Our study confirmed that CS induced a systemic cytokine/chemokine
release. Twenty-four cytokines/chemokines were measured, and 14 were
detectable. Of the 14 detected, 12 were pro-inflammatory, 1 was antiinflammatory, and 1 had both a pro- and an anti-inflammatory effect. Six of the 14
cytokines/chemokines that were detectable were significantly elevated from their
baseline levels after 2hrs of CS (p<0.05). These included TNF-α (Figure 2.2), IL1β (Figure 2.3), GRO/KC (Figure 2.4), MCP-1 (Figure 2.5), MIP-1α (Figure 2.6),
and IL-10 (Figure 2.7). TNF-α, IL-1β, GRO/KC, MCP-1, and MIP-1α are proinflammatory cytokines/chemokines, while IL-10 is an anti-inflammatory cytokine.
These results confirm that CS induces a significant and, predominantly, proinflammatory response.

4.1.4 TNF-α Neutralization
The purpose of this study was to evaluate the microvascular dysfunction,
inflammatory response, and tissue injury following the neutralization of TNF-α at
the time of fasciotomy, in an animal model of CS. TNF-α is a potent proinflammatory cytokine released in response to trauma, inflammation, or infectious
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stimulation (Stein and Gordon 1991). Previously, multiple I/R studies have
demonstrated that TNF-α is up-regulated in as little as 1 hour following
reperfusion (Caty, Guice et al. 1990, Brock, Lawlor et al. 1999, Krishnadasan,
Naidu et al. 2003). TNF-α acts as a chemoattractant for neutrophils, causes upregulation

of

downstream

cytokine/chemokine

production,

promotes

the

expression of adhesion molecules, and activates cell death via apoptosis and
necroptosis (Ascer, Gennaro et al. 1992, Yi and Ulich 1992, Seekamp, Warren et
al. 1993, Zhang, Hu et al. 2005, Parameswaran and Patial 2010).
CS causes a shift in perfusion from CPC (under normal physiological
conditions) to that of IPC and NPC. The neutralization of TNF-α at the time of
fasciotomy essentially had no effect on the microvascular perfusion profile seen
in CS (Figure 3.1). Modulation of the inflammatory response did not, therefore,
provide protection in restoring microvascular perfusion in the face of raised ICP.
These results corroborate previous work by our group, whereby a leukocytedeplete animal model was not shown to be protective in restoring the
microvascular perfusion following a CS insult (Lawendy, Bihari et al. 2015).
The results of this study, again, confirm that CS induces a systemic
inflammatory response. Two hours of CS produced a significant increase in
serum TNF-α, coupled with the recruitment of activated leukocytes (Figure 3.5).
Modifying the inflammatory response post-fasciotomy, through the administration
of TNF-α neutralizing antibody, significantly decreased leukocyte activation, as
evidenced by a decrease in both rolling and adherent leukocytes within the postcapillary venules (p<0.05 and p<0.0001 respectively) (Figure 3.3 and Figure 3.4).
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When compared to control animals, neutralization of TNF-α led to a

significant relative reduction of approximately 36% in tissue injury (Figure 3.2)
following elevated ICP. This data confirms that TNF-α plays at least some role in
the inflammatory response observed in a CS insult. In a leukocyte-deplete animal
model of CS, tissue injury was reduced by more than 50%, implying that there
are also other cytokines/chemokines involved in the pathophysiology of CS
(Lawendy, Bihari et al. 2015).
Our findings confirm that CS is associated with a significant up-regulation
of the systemic inflammatory response, and its induction should, therefore, be
considered in the pathophysiology of CS. TNF-α plays a role in the tissue injury
associated with CS, at least in the acute phase. Neutralizing TNF-α in isolation
had less of an effect on reducing tissue injury in comparison to a completely
leukocyte deplete animal model, suggesting that other cytokines/chemokines
may also contribute to the pathophysiology of CS (Lawendy, Bihari et al. 2015).
There are, of course, multiple potential mechanisms of tissue injury, including the
generation of reactive oxygen species, increased expression of adhesion
molecules on the surface of leukocytes and endothelial cells, and direct
parenchymal injury via extravasated leukocytes (Gute, Ishida et al. 1998).
TNF-α as been recognized in initiating cell death via apoptosis and
necroptosis (Wu, Tan et al. 2011). Necroptosis, in particular, is associated with
pathological conditions including I/R; and, in contrast to apoptosis, it generates
an inflammatory response (Vandenabeele, Galluzzi et al. 2010, Linkermann and
Green 2014). It is, therefore, plausible that the low-flow ischemia associated with
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CS, and consequently the early and sustained reperfusion injury, stimulates an
earlier and sustained trigger of the apoptotic and necroptotic pathways. This
could in part, account for the greater tissue injury associated with CS versus
complete I/R.

4.2 LIMITATIONS AND FUTURE DIRECTIONS
Inflammation has been shown to play an important role in the
microvascular dysfunction and tissue injury associated with CS. One of the
limitations of these studies is its use of a small animal model. The injury process
and clinical significance of the observed decrease in tissue injury remain to be
translated to a human model. Future directions would include a large animal
model, whose physiology more resembles that of humans, and recovery studies
in order to assess functional outcomes.
The study also validates immune modulation as a potential therapeutic
target in order to decrease the tissue injury associated with CS. TNF-α is already
a mainstay of treatment in chronic pro-inflammatory conditions, such as Crohn’s
disease, rheumatoid arthritis, and psoriasis (Ford, Sandborn et al. 2011). TNF-α
is only one of many cytokines/chemokines that were found to be significantly upregulated following CS. Targeting different cytokines/chemokines, or a
combination of them, could further elucidate the pathophysiological mechanism
of CS.
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4.3 CONCLUSIONS
The maintenance of microvascular perfusion throughout the CS insult
allows oxygenated blood to enter an essentially ischemic compartment, which
ultimately leads to the early initiation of the inflammatory cascade, and activation
of leukocytes. This, in turn, stimulates the release of predominantly proinflammatory cytokines/chemokines, and in particular, the production of TNF-α.
Neutralization confirms that TNF-α plays a role in the tissue injury associated
with CS, likely through early activation of the apoptotic and necroptotic pathways.
The systemic inflammatory response is a complex and redundant system,
and continued investigation is still required, as this study has only begun to
elucidate one small piece of a complex pathophysiological mechanism.
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APPENDIX A: ANIMAL PROTOCOL APPROVAL LETTER

	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
  
	
  

	
  

	
  
	
  

	
  
	
  

	
  
	
  

	
  
	
  

	
  

	
  

	
  

	
  
	
  
	
  
11.01.13	
  
*This	
  is	
  the	
  original	
  approval	
  for	
  this	
  protocol*	
  
*A	
  full	
  protocol	
  submission	
  will	
  be	
  required	
  in	
  2017*	
  

	
  
Dear	
  Dr.	
  Lawendy:	
  
	
  
Your	
  animal	
  use	
  protocol	
  form	
  entitled:	
  
	
  
Direct	
  and	
  Remote	
  Organ	
  Injury	
  Following	
  Hind	
  Limb	
  Compartment	
  Syndrome	
  
	
  
Funding	
   agency	
   Orthopaedic	
   Trauma	
   Association	
   –	
   Direct	
   and	
   Remote	
   Organ	
   Injury	
   Following	
   Hind	
   Limb	
  
Compartment	
  Syndrome	
  –	
  Grant	
  #R4889A04	
  has	
  been	
  approved	
  by	
  the	
  University	
  Council	
  on	
  Animal	
  Care.	
  
	
  
This	
  approval	
  is	
  valid	
  from	
  11.01.13	
  to	
  11.30.17	
  with	
  yearly	
  renewal	
  required.	
  
	
  
The	
  protocol	
  number	
  for	
  this	
  project	
  is	
  2009-‐083.	
  
	
  
1.	
  	
  This	
  number	
  must	
  be	
  indicated	
  when	
  ordering	
  animals	
  for	
  this	
  project.	
  
2.	
  	
  Animals	
  for	
  other	
  projects	
  may	
  not	
  be	
  ordered	
  under	
  this	
  number.	
  
3.	
  	
  If	
  no	
  number	
  appears	
  please	
  contact	
  this	
  office	
  when	
  grant	
  approval	
  is	
  received.	
  
If	
   the	
   application	
   for	
   funding	
   is	
   not	
   successful	
   and	
   you	
   wish	
   to	
   proceed	
   with	
   the	
   project,	
   request	
   that	
   an	
  
internal	
  scientific	
  peer	
  review	
  be	
  performed	
  by	
  the	
  Animal	
  Use	
  Subcommittee	
  office.	
  
4.	
   	
   Purchases	
   of	
   animals	
   other	
   than	
   through	
   this	
   system	
   must	
   be	
   cleared	
   through	
   the	
   ACVS	
   office.	
   Health	
  
certificates	
  will	
  be	
  required.	
  
	
  
ANIMALS	
  APPROVED	
  FOR	
  4	
  YEARS	
  
Species
Strain
Other Detail
Pain
Animal # Total
Level
for 4 years
Rat
Wistar
150-350 g
C
680
Pig
Yorkshire-Landrace
50-60 kg
B
30
	
  
REQUIREMENTS/COMMENTS	
  
Please	
   ensure	
   that	
   individual(s)	
   performing	
   procedures	
   on	
   live	
   animals,	
   as	
   described	
   in	
   this	
   protocol,	
   are	
  
familiar	
  with	
  the	
  contents	
  of	
  this	
  document.	
  
	
  
The	
  holder	
  of	
  this	
  Animal	
  Use	
  Protocol	
  is	
  responsible	
  to	
  ensure	
  that	
  all	
  associated	
  safety	
  components	
  (biosafety,	
  
radiation	
   safety,	
   general	
   laboratory	
   safety)	
   comply	
   with	
   institutional	
   safety	
   standards	
   and	
   have	
   received	
   all	
  
necessary	
  approvals.	
  Please	
  consult	
  directly	
  with	
  your	
  institutional	
  safety	
  officers.	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
c.c.	
  	
  R	
  Bihari,	
  T	
  Carter,	
  K	
  Bothwell,	
  P	
  Coakwell	
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Dear Dr Erin Donohoe
We hereby grant you permission to reproduce the material detailed below at no charge in your thesis, in
print and on Western Library’s Scholarship@Western program.subject to the following conditions:
1.
If any part of the material to be used (for example, figures) has appeared in our publication
with credit or acknowledgement to another source, permission must also be sought from that
source. If such permission is not obtained then that material may not be included in your
publication/copies.
2.
Suitable acknowledgment to the source must be made, either as a footnote or in a reference
list at the end of your publication, as follows:
“This article was published in Publication title, Vol number, Author(s), Title of article, Page Nos,
Copyright Elsevier (or appropriate Society name) (Year).”
3.

Your thesis may be submitted to your institution in either print or electronic form.

4.
Reproduction of this material is confined to the purpose for which permission is hereby
given.
5.
This permission is granted for non-exclusive world English rights only. For other
languages please reapply separately for each one required. Permission excludes use in an
electronic form other than as specified above. Should you have a specific electronic project in
mind please reapply for permission.
6.
This includes permission for the Library and Archives of Canada to supply single copies,
on demand, of the complete thesis. Should your thesis be published commercially, please reapply
for permission.

Yours sincerely

Jennifer Jones
Permissions Specialist
Elsevier Limited, a company registered in England and Wales with company number 1982084, whose
registered office is The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom.

	
  

80	
  

APPENDIX C
Surgical Approach to Leg Compartment Syndrome
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APPENDIX C: SURGICAL APPROACH TO LEG COMPARTMENT
SYNDROME

There are multiple surgical techniques for complete fascial release of the
lower leg. These include a two-incision fasciotomy, a single-incision perifibular
fasciotomy, and fibulectomy. The preferred method is the two-incision technique
(described below), as it allows for adequate visualization of all compartments,
assessment of muscle viability, and sufficient exposure to safely avoid injury to
the neurovascular structures.

C1. Two-Incision Fasciotomy (Mubarak and Hargens 1981)
The patient is positioned supine on the operating room table. A tourniquet
is applied above the knee, but not insufflated. The limb is prepped and draped
free. A 25 cm incision is made, centered halfway between the fibular shaft and
the tibial crest (Figure C1). The subcutaneous tissue is dissected and full
thickness skin flaps are elevated in order to achieve wide exposure of the fascial
compartments. The intermuscular septum is exposed, and the superficial
peroneal nerve is identified distally, lying posterior to the septum. Using
dissecting scissors, the anterior compartment is released proximally and distally,
in line with the tibialis anterior. The lateral compartment is released proximally
and distally, in line with the fibular shaft. Care must be taken at the distal end to
avoid damaging the superficial peroneal nerve.
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A second longitudinal incision 2 cm posterior to the posterior margin of the

tibia is made. The subcutaneous tissue is dissected, and full thickness skin flaps
are elevated for exposure. The saphenous vein and nerve are identified and
protected. The septum between the deep and superficial posterior compartments
is identified. The superficial posterior compartment is released by incising the
fascia along the entire length of the gastrocnemius-soleus complex. The deep
posterior compartment is released by incising the fascia over the flexor digitorum
longus muscle. Proximally, if the soleus bridge extends more than halfway down
the tibia, this extended origin must be released. Finally, after release of the
posterior compartment the tibialis posterior muscle must be identified. If there is
increased tension within this compartment, it is released.
Wounds are left open and packed, and a posterior plaster splint is applied
with the foot plantigrade.

C2. REFERENCES
Lawendy, A. and D. Sanders (2010). Operative Techniques: Orthopaedic Trauma
Surgery, Saunders.
Mubarak, S. J. and A. R. Hargens (1981). Compartment syndromes and
Volkmann's ischemic contracture. Philadelphia, WB Saunders.
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Figure D2: Two-incision fasciotomy. An incision in the anterior compartment is

Figure C1.centered
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The anterior compartment is released proximally and distally in line with the

septum is exposed and the superficial peroneal nerve is identified.
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Reproduced
permission
from Lawendy
Sanders (2010).
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superficial posterior compartment is released by incising the fascia
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over the entire length of the gastrocnemius-soleus complex. Finally,
the deep posterior compartment is released with a fascial incision
overlying the flexor digitorum longus muscle.
Reproduced with permission from Lawendy and Sanders (2010).
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APPENDIX D
Luminex x-MAP Assay Protocol
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APPENDIX D: LUMINEX x-MAP ASSAY PROTOCOL

Sera

were

subjected

to

a

cytokine/chemokines

multiplex

panel

(MILIPLEX® MAP, EMD Millipore, St. Charles, MO), based on Luminex® x-MAP
technology,

simultaneously

quantifying

the

expression

of

24

different

cytokines/chemokines: Eotaxin, G-CSF, GM-CSF, IL-1α, MCP-1, leptin, MIP-1α,
IL-4, IL-1β, IL-2, IL-6, IL-9, IL-13, IL-10, IL-12p70, IL-5, IFN-γ, IL-17, IL-18, IP-10,
GRO/KC, RANTES, TNF-α, VEGF. This immunoassay technology uses
fluorescently labelled microsphere beads.
In principle, internally colour-coded microspheres are coated with two
fluorescent dyes. Through precise concentrations of these, a hundred distinctly
coloured bead sets can be created, each of which is coated with a specific
capture antibody. After an analyte from a test sample is captured by the bead, a
biotinylated detection antibody is introduced. The reaction mixture is then
incubated with the reporter conjugate (streptavidin-phycoerythrin) to complete the
reaction on the surface of each microsphere. The microspheres are allowed to
pass rapidly through a laser, which excites the internal dyes marking the
microsphere set. A second laser excites phycoerythrin, the fluorescent dye on
the reporter molecule. Finally, high-speed digital-signal processors identify each
individual microsphere and quantify the result of its bioassay based on
fluorescent reporter signals, comparing it to the standard curve.
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All samples were run in duplicate. Standard curve was obtained by

performing serial dilutions of rat standard containing all 24 cytokines/chemokines;
20,000pg/ml, 5,000pg/ml, 1,250pg/ml, 312.5pg/ml, 78.13pg/ml, 19.53pg/ml,
4.88pg/ml and 0pg/ml were used to run the standard curve. 25µl of each sample
or standard, followed by 25µl of beads were added to the appropriate wells on a
96-well plate, and incubated with agitation overnight at 4°C. Following two
washes with the wash buffer, 25µl of detection antibody were added to each well,
and incubated for 2 hours at room temperature. This was followed by addition of
25µl of phycoerythrin to each well and 30-minute incubation at room temperature.
The plate was washed two times with wash buffer; 150µl of sheath fluid was then
added to each well to reconstitute the microbeads. The plate was then read on
Luminex200 instrument equipped with MILLIPLEX® Analyst 5.1 software,
recording the median fluorescent intensity (MFI). The results were calculated by
4-point logistic curve fitting software against the MFI of the standards.
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